Gilead Sciences

Livdelzi is accelerating into a competitive vacuum. Q4 2025 revenue $150M (+42% sequentially), >50% US market share in 2L PBC. Ocaliva withdrawal creates near-monopoly with no branded competitor on the horizon. PBC is chronic and lifelong — every new start is annuitized revenue. Diagnosis rates expanding as awareness grows. The $1.5B consensus peak assumes competitive re-entry that may not come for 3-4 years. In a monopoly scenario with improving diagnosis, $2-2.5B peak is plausible. Revenue is masked in the "Liver Disease" segment alongside declining HCV products — the Q4 segment grew 17% YoY but investors see "liver" and think hepatitis C tail.

PBC is a small indication (~110K diagnosed patients in the US). Even with monopoly, the ceiling is limited. New entrants (elafibranor, other PPARs, FXR agonists) could break the monopoly within 2-3 years. Seladelpar is a niche drug in a niche disease — it moves the EPS needle but does not change the GILD story.

CAR-T maintains a durable efficacy advantage (deeper responses, potential cure) that justifies complexity and cost. Anito-cel safety profile (8% ICANS, zero delayed neurotoxicities) differentiates from both other CAR-Ts and bispecifics. Manufacturing improvements reduce vein-to-vein time. Earlier-line expansion (1L high-risk LBCL for Yescarta, 2L+ MM for anito-cel) captures patients before bispecifics.

Bispecifics (epcoritamab/Epkinly, glofitamab/Columvi, talquetamab/Talvey) are off-the-shelf, available same-day, cost 1/3 to 1/5 of CAR-T, and can be administered in community settings. As efficacy data matures and combination regimens improve, the efficacy gap narrows. Payers will increasingly mandate bispecifics before CAR-T. Kite FY25 revenue already declining -7% YoY. Anito-cel launches into a myeloma market where bispecifics are entrenched. Combined Kite + anito-cel peak of ~$5B may be capped at $2-3B if CAR-T becomes salvage-only. That is a $15-25B NPV difference.